Common Bile Acid Supplement Enhanced Cancer Radiation Therapy
Researchers found that a bile acid supplement may help overcome a specific immune barrier in human tumors during radiation.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Do you trust that new medical research discoveries will reliably improve cancer treatment options for patients?
Scientists have identified a mechanism in human tumors that blunts the immune-boosting effects of radiation therapy. This pathway, which is absent in mouse models, may be targeted by ursodeoxycholic acid to improve cancer treatment outcomes.
Why it matters
Radiotherapy is used in more than half of all cancer patients, yet tumors often evade the resulting immune response. This discovery provides a new target for drug therapies that could make radiation more effective by preventing the shutdown of immune signaling.
A preclinical study identified an FXR-TRIM22-STAT1 immune checkpoint that suppresses radiation-induced immunity in human tumors, a feature missing in mouse models. Researchers demonstrated that ursodeoxycholic acid acts as an FXR antagonist to restore immune signaling in humanized mouse models.
The players
Ursodeoxycholic acid
A bile acid supplement traditionally used to treat liver conditions that researchers found can act as an FXR antagonist.
The details
Ionizing radiation typically triggers immune pathways, but it also stabilizes a nuclear receptor called FXR via USP7-dependent deubiquitination. This stabilization induces the E3 ligase TRIM22, which degrades STAT1 and suppresses the body's natural interferon-stimulated immune response. Ursodeoxycholic acid disrupts this process by suppressing radiation-induced TRIM22, thereby protecting STAT1 and enhancing the effectiveness of radiotherapy in human tumor models.
Timeline
September 30, 2026: The study detailing this immune checkpoint mechanism was published.
Health Landscape
This finding advances the field of radioimmunotherapy by addressing the long-standing discrepancy between mouse model results and human clinical outcomes. It highlights the importance of targeting human-specific immune evasion pathways to improve standard radiation protocols.
This preclinical discovery is a starting point for potential future therapies rather than an immediate change to current cancer care. Patients currently undergoing radiotherapy should discuss any questions regarding immune system management directly with their oncologist.
The takeaway
Understanding how tumors silence immune responses during radiation is critical for improving future cancer therapies. Stay informed by discussing new research findings and their relevance to specific treatment plans with a qualified physician.
Further reading
For more on the latest research and clinical innovations in oncology, visit our Cancer section.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that new medical research discoveries will reliably improve cancer treatment options for patients?
